Breast cancer research : BCR
[225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer.
Anjong Florence Tikum, Dede Api Fon, Fabrice Ngoh Njotu, Nikita Henning, Emmanuel Nwangele, Hanan Babeker, Jessica Pougoue Ketchemen, Alireza Doroudi, Maruti Uppalapati, Humphrey Fonge
Published: 202610.1186/s13058-026-02220-z
Abstract
BACKGROUND: EGFR is overexpressed in TNBC, and "naked" anti-EGFR monoclonal antibodies have been evaluated in clinical trials with dismal effectiveness. Matuzumab is an anti-EGFR monoclonal antibody that can be used to develop theranostics. We posit…
Preview only. Read the full abstract at the source